Syndax Pharmaceuticals (SNDX) Net Income towards Common Stockholders (QoQ) (2015 - 2026)

Syndax Pharmaceuticals (SNDX) Net Income towards Common Stockholders (QoQ) (2015 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn
7 Belite Bio 62.72 Bn 62.72 Bn -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn
9 Revolution Medicines 37.35 Bn 37.35 Bn -
10 Syndax Pharmaceuticals 1.83 Bn 1.48 Bn 53.02 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 27.10%
Dec 31, 2025 3.70%
Sep 30, 2025 20.19%
Jun 30, 2025 10.44%
Mar 31, 2025 10.16%
Dec 31, 2024 -11.85%
Sep 30, 2024 -12.07%
Jun 30, 2024 7.57%
Mar 31, 2024 -42.14%
Dec 31, 2023 -11.06%
Sep 30, 2023 -1.93%
Jun 30, 2023 -9.96%
Mar 31, 2023 -32.89%
Dec 31, 2022 1.58%
Sep 30, 2022 11.69%
Jun 30, 2022 -4.08%
Mar 31, 2022 -140.06%
Dec 31, 2021 562.87%
Sep 30, 2021 10.29%
Jun 30, 2021 17.33%